IWM
ZYNE

IHT Wealth Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

IHT Wealth Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-11,450
Closed -$87K – 652
2019
Q3 		$87K Buy
+11,450
New +$129K 0.01% 590

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

IHT Wealth Management's ZYNE Position: Q4 2019 in Review

IHT Wealth Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2019, closing a stake of 11,450 shares — an estimated $87K sold.

IHT Wealth Management first reported a position in ZYNE in Q3 2019 and held it in 1 quarter. The position peaked at $87K in Q3 2019. 79 funds tracked by Wall St. Rank hold ZYNE as of Q4 2019.

  • IHT Wealth Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2019 after selling out during the quarter.
  • IHT Wealth Management sold 11,450 Zynerba Pharmaceuticals, Inc shares in Q4 2019, an estimated $87K.
  • IHT Wealth Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2019 and held it in 1 quarter.
  • IHT Wealth Management's Zynerba Pharmaceuticals, Inc position peaked at $87K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2019.

Based on IHT Wealth Management's 13F filing for Q4 2019, filed 18 Feb 2020.